BNP B Type Natriuretic Peptide Chemiluminescencross For Automatic Immunoassay Analyzer In Cardiac Marker

CLIA Reagents of Inflammation (BNP)

【Expected usage】
Brain natriuretic peptide detection kit (magnetic particle chemiluminescence method) (hereinafter referred to as this kit) is used to quantitatively detect the content of brain natriuretic peptide in human plasma in vitro.

Heart failure is an important clinical syndrome, mainly manifested as left ventricular systolic or diastolic dysfunction, or both systolic and diastolic dysfunction. Heart failure occurs when the heart cannot pump blood at a certain rate to meet the needs of tissue metabolism. The most common causes are coronary heart disease, hypertension, heart valve disease and cardiomyopathy. Accurate and early diagnosis of heart failure allows timely and effective therapeutic interventions (eg, angiotensin-converting enzyme inhibitors, beta-blockers), thereby improving heart failure morbidity and mortality. According to the New York Heart Association classification (NYHA classification I–IV), according to clinical signs and symptoms, heart failure can be divided into 4 grades, and the severity of the disease increases gradually.

The natriuretic peptide system is a large class of peptides that are structurally similar but genetically distinct. It includes atrial natriuretic peptide (ANP) and cardiomyocyte-derived B-type natriuretic peptide and endothelial cell-derived C-type natriuretic peptide. The common feature of these polypeptides is a 17-amino acid cyclic structure formed by connecting two cysteine ​​residues with one disulfide bond. Cardiac natriuretic peptide is a natural antagonist of the renin-angiotensin-aldosterone system and the sympathetic nervous system. They promote natriuresis and diuresis, have vasodilatory effects, and exert anti-mitotic effects in cardiovascular tissue. The heart secretes and releases ANP and BNP in response to changes in hemodynamic pressure.

In the human body, B-type natriuretic peptide is mainly produced by the heart and is released as the pressure on the heart increases. Many studies have shown that an increase in B-type natriuretic peptide is found in the circulating blood of patients with early congestive heart failure. With the continuous aggravation of congestive heart failure, the content of B-type natriuretic peptide in the blood also increased. BNP testing provides an objective, non-invasive method for the assessment of patients with heart failure and risk stratification of acute coronary syndromes.
At present, the clinical methods for detecting the content of brain natriuretic peptides include radioimmunoassay, enzyme-linked immunosorbent assay, colloidal gold method, immunoturbidimetric method and chemiluminescence immunodiagnosis method.

【Inspection Principle】
This kit adopts the principle of direct sandwich method, uses magnetic microparticles as the solid phase of the immune reaction, and uses chemiluminescence enzyme-linked immunoassay method and chemiluminescence measuring instrument to determine the content of brain natriuretic peptide in human plasma.

The technical principle is: Fluorescein isothiocyanate (FITC)-labeled mouse monoclonal anti-BNP antibody combines with alkaline phosphatase (AP)-labeled BNP paired antibody and BNP in samples, calibrators or quality controls to form "" Sandwich" complex. Then, the magnetic particles linked with the anti-FITC antibody are added, and the antigen-antibody immune complex is bound to the magnetic particles through the specific binding of the anti-FITC antibody and FITC.

Under the action of an external magnetic field, the complex formed by the immune reaction is separated from other unbound substances, and after washing the complex, an enzymatic chemiluminescence substrate is added. The substrate is catalytically cleaved under the action of the enzyme to form an unstable excited state intermediate.

When the excited state intermediate returns to the ground state, photons are emitted to form a luminescence reaction, and the luminescence intensity of the reaction can be detected by a chemiluminescence instrument. In the range of detection wavelength (230-700nm), the luminescence intensity is proportional to the content of BNP in the sample, and the BNP concentration in the sample can be calculated by fitting the modified four-parameter Logistic equation.

Zecen Biotech CO., LTD., founded in 2011, is a leading Chinese diagnostics manufacturer specializing in in-vitro diagnostics devices and reagents. Zecen focus on the Chemiluminescent immunoassay (CLIA) field. With all products CE marked, our market presence currently spreads from across China to other countries including India, Switzerland, Russia etc., Zecen is expanding its footprint to become a global brand.

Zecen is the only enterprise with independent intellectual property rights in the entire chemiluminescence industry chain in China, including reagent, instrument, magnetic microbead, and reagent raw material. Our current products include more than 100 assays, from thyroid, inflammation, diabetes, tumer markers, immune disorders, hormones to cardiac markers. Our ever-expanding test menu helps our customers and collaborators keep up with the demands of healthcare sector. Zecen is striving for innovation and perfection to deliver the best products to the customers.

As a manufacturer, Zecen provide the OEM, ODM and other customized service of all products. We have the core R&D centers and innovative ability to lay a solid foundation for developing the broadest range of CLIA analyzers and test menu. High-quality sales and after-sales links provide the more intimate service. The patent and CE certification give us the confident sending all over the world, and more than 50 companys in the requiement of customized and have a long term coorperation with Zecen.